New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
10:00 EDTWAG, TKPPY, TRN, ZU, NZT, KRA, BC, MTTRY, GHL, ALSMY, RDS.A, MW, EVR, RHOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alstom (ALSMY) upgraded to Buy from Hold at Deutsche Bank... Brunswick (BC) upgraded at KeyBanc... Evercore Partners (EVR) upgraded to Buy from Hold at Sandler O'Neill... Greenhill & Co. (GHL) upgraded to Buy from Hold at Sandler O'Neill... Kraton Performance (KRA) upgraded at Oppenheimer... Men's Wearhouse (MW) upgraded to Outperform from Market Perform at Cowen... Metro (MTTRY) upgraded to Neutral from Underweight at JPMorgan... Restoration Hardware (RH) upgraded at BofA/Merrill... Royal Dutch Shell (RDS.A) upgraded to Overweight from Equal Weight at Morgan Stanley... Technip (TKPPY) upgraded to Outperform from Neutral at Credit Suisse... Tel. Corp of New Zealand (NZT) upgraded to Buy from Neutral at BofA/Merrill... Trinity Industries (TRN) upgraded to Buy from Neutral at UBS... Walgreens (WAG) upgraded to Buy from Hold at Jefferies... zulily (ZU) upgraded to Buy from Neutral at Goldman.
News For A;TKPPY;NZT;TRN;WAG;ZU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
10:12 EDTAHigh option volume stocks
High option volume stocks: A RS ALXN AVGO TFM PLKI JNPR VGK GDOT
08:38 EDTAAgilent authorizes repurchase of up to $1.14B of common stock
Agilent Technologies announced that its board of directors has approved a new share repurchase program. The 2015 Stock Repurchase Program authorizes the purchase of up to $1.14B of the company’s common stock through and including Nov. 1, 2018. The new program will commence, at the option of the company, on either Nov. 1, 2015, or the date on which the company completes the purchase of $365M of common stock under the existing stock repurchase program in fiscal 2015. Upon commencement, the new repurchase program replaces Agilent’s existing stock repurchase program, which authorized the repurchase of shares to reduce or eliminate share dilution from equity programs.
May 24, 2015
16:20 EDTAAgilent to host analyst meeting
Subscribe for More Information
May 20, 2015
16:29 EDTAAgilent appoints Rodney Gonsalves as principal accounting officer
Subscribe for More Information
May 18, 2015
19:12 EDTAOn The Fly: After Hours Movers
Subscribe for More Information
18:03 EDTTRNThe Federal Highway Administration updates highway guardrail review criteria
The Federal Highway Administration, FWHA, posted the following on its website: "In remarks made at the American Association of State Highway and Transportation Officials 2015 Spring Meeting in Cheyenne, Wyoming, on Friday, Federal Highway Administration Acting Administrator Gregory Nadeau announced a series of actions that will apply to the reimbursement eligibility process for states purchasing and installing guardrails, their components and other devices. FHWA is accelerating the transition to the latest crash test criteria for road safety hardware. Specifically, beginning on January 1, 2016, any proposed modification to a roadside safety device will require meeting full-scale crash test criteria outlined under AASHTO’s Manual for Assessing Safety Hardware, even if the device was previously tested and met National Cooperative Highway Research Program Report 350 criteria. “Our goal is to make our roads, bridges and highways as safe as possible, in part by accelerating the move to the newer crash test criteria,” Nadeau said. FHWA is also increasing transparency in its process for determining whether a specific device is eligible for federal reimbursement. In a letter to industry and other stakeholders, FHWA announced that it will require manufacturers and test labs to disclose all financial interests. FHWA has also recently commissioned an independent end-to-end review of the entire roadside safety hardware process from development and testing through field performance." The Fly notes that there is an ongoing probe of the safety of guardrails manufactured by Trinity Industries (TRN). Reference Link
17:15 EDTAAgilent down almost 5% after Q2 earnings results, guidance
16:10 EDTAAgilent sees FY15 EPS $1.67- $1.73, consensus $1.69
Subscribe for More Information
16:07 EDTAAgilent sees Q3 EPS 38c-42c, consensus 42c
Sees Q3 revenue $995M-$1.015B, consensus $1B.
16:06 EDTAAgilent reports Q2 EPS 38c, consensus 39c
Subscribe for More Information
15:00 EDTANotable companies reporting after market close
Subscribe for More Information
May 15, 2015
17:23 EDTZUAlibaba reports 17.2% passive stake in zulily
Subscribe for More Information
16:21 EDTZUStocks end week little changed as data, deals offset bond yield jumps
Stocks ended the week little changed as a number of M&A deals and a few relatively strong economic data points offset worries about rising bond yields. MACRO NEWS: U.S. weekly jobless claims came in better than expected and reached the lowest four-week average level in 15 years... In Europe, the combined GDP of the 19 eurozone countries grew 0.4% in the first quarter, which was a bit weaker than the 0.5% consensus growth forecast but a pickup from the 0.3% growth pace of the final quarter of last year. Of note, all four of the euro zone's largest economies recorded growth in the same quarter for the first time since the first half of 2010... The People's Bank of China reduced its one year interest rate by 0.25%, marking the third time in the last six months that the central bank has cut benchmark rates... Bond yields surged in many of the world's largest economies, raising worries about inflation and putting pressure on stocks in the beginning of the week. COMPANY NEWS: There was a significant amount of M&A activity again this week, with the headliner being Verizon's (VZ) deal to acquire AOL (AOL) for $50 per share in a transaction valued at $4.4B. Danaher (DHR) agreed to buy purification technologies supplier Pall Corporation (PLL) for $127.20 per share in cash. Danaher also announced that it plans to split itself into two publicly traded companies. Energy infrastructure company Williams (WMB) announced a simplification deal to buy its affiliate Williams Partners (WPZ) for $13.9B in an all-stock transaction. Energy exploration company Noble Energy (NBL) agreed to acquire Rosetta Resources (ROSE) in an all-stock deal. Noble is buying Rosetta for $2.1B in stock plus the assumption of Rosetta's net debt of $1.8B... Alibaba (BABA) acquired a 9.3% stake in Zulily (ZU), an e-commerce retailer geared toward women. A person familiar with the matter reportedly told the Wall Street Journal that the Chinese e-commerce giant is not pursuing an outright acquisition of the U.S. company, however... Shares of Netflix (NFLX) jumped Friday and hit a new all-time high after Bloomberg reported that the company is in talks with Wasu Media, a Chinese media company backed by Alibaba Executive Chairman Jack Ma, about forming a partnership to bring its content to China... Nelson Peltz's Trian Fund Management lost its proxy fight with DuPont (DD) as Trian did not succeed in getting its nominees elected to the DuPont board. INDEXES: For the week, the Dow rose 0.45% to 18,272.56, the Nasdaq gained 0.89% to 5,048.29, and the S&P 500 climbed 0.31% to 2,122.73.
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use